Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ATA3219 |
Trade Name | |
Synonyms | ATA 3219|ATA-3219 |
Drug Descriptions |
ATA3219 comprises allogeneic Epstein-Barr Virus (EBV)-targeted T-cells engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially induce killing of CD19-expressing tumor cells and decrease tumor growth (Blood (2020) 136 (Supplement 1): 9). |
DrugClasses | CD19 Antibody 21 CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ATA3219 | ATA3219 | 0 | 1 |